南财智讯1月30日电，九鼎投资发布业绩预亏公告，本公司预计2025年度实现归属于上市公司股东的净 利润-35000万元到-30000万元，与上年同期相比，亏损将增加。业绩预亏的主要原因：1、公司私募股 权投资管理业务收入、在管项目估值及参股公司业绩持续下滑：（1）存量基金进入退出期导致管理费 收入减少；（2）项目退出收益较上年同期下降导致公司收取的管理报酬收入减少；（3）在管项目估值 下降导致公司自有资金投资公允价值损失较高；（4）参股公司持续亏损导致公司投资损失较大。2、公 司房地产业务部分资产预计减值、终止确认部分递延所得税资产：（1）考虑到当前房地产行业的整体 现状仍不容乐观，公司房地产项目所在区域的市场环境亦相对紧张，市场价格持续下行等多重不利因 素，结合公司房地产项目的具体实际情况，公司依据相关会计准则，对房地产存货进行了初步的减值测 试。遵循谨慎性原则，公司预计将对部分房地产存货进一步计提存货跌价准备，预计金额约为1.36亿 元；（2）受市场需求疲软、周边写字楼租金价格下降等影响，公司初步预计投资性房地产的公允价值 较去年进一步下降，将导致报告期发生公允价值变动损失约为0.4亿元。（3）基于审慎性 ...

证券之星消息，1月27日多元金融板块较上一交易日下跌1.45%，越秀资本领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。多元金融板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002961 | 瑞达期货 | 3080.84万 | 5.81% | -714.56万 | -1.35% | -2366.27万 | -4.46% | | 600053 | 九鼎投资 | 1888.21万 | 5.74% | -460.64万 | -1.40% | -1427.56万 | -4.34% | | 000935 四川双马 | | 1049.03万 | 5.35% | 519.78万 | 2.65% | -1568.81万 | -8.01% | | 603093 | 南华期货 | 546.38万 | 2.33% | 299.24万 | 1.27% | -84 ...

Core Viewpoint - As of January 20, a total of 142 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Fenglong Co., which has seen net buying for 15 consecutive trading days [1] - Other notable stocks with significant net buying days include Anhui Heli, *ST Guohua, Kangchen Pharmaceutical, Jiuding Investment, Shaanxi Coal and Electricity, Yili Co., Microelectrophysiology, and Gansu Expressway [1]

Market Overview - The diversified financial sector experienced a decline of 1.09% on January 16, with Aijian Group leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] Stock Performance - Jiuding Investment (600053) saw a significant increase of 10.00%, closing at 23.10 with a trading volume of 227,700 shares and a turnover of 503 million yuan [1] - ST Rendo (002647) rose by 4.99% to close at 9.46, with a trading volume of 229,800 shares and a turnover of 215 million yuan [1] - Guowang Yingda (600517) increased by 3.13% to 6.58, with a trading volume of 1,221,400 shares and a turnover of 820 million yuan [1] - Aijian Group (600643) fell by 7.75% to 5.12, with a trading volume of 509,300 shares and a turnover of 267 million yuan [2] - Lakala (300773) decreased by 5.37% to 28.56, with a trading volume of 1,018,900 shares and a turnover of 2.978 billion yuan [2] Capital Flow - The diversified financial sector saw a net outflow of 792 million yuan from main funds, while retail investors contributed a net inflow of 466 million yuan [2] - The main funds showed a net inflow in Jiuding Investment of 62.62 million yuan, while Guowang Yingda had a net inflow of 53.86 million yuan [3] - ST Rendo experienced a net inflow of 34.81 million yuan from main funds, but also saw significant outflows from retail investors [3]

Group 1 - The diversified financial sector increased by 1.99% on January 12, with Ailian Development leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] - Ailian Development's stock price rose to 6.28, marking a 9.98% increase, with a trading volume of 535,700 shares and a transaction value of 334 million [1] Group 2 - The diversified financial sector experienced a net outflow of 22.34 million from institutional investors and 78.83 million from retail investors, while retail investors saw a net inflow of 101 million [2] - The trading data indicates that LaKala had a net inflow of 62.44 million from institutional investors, despite a net outflow of 71.21 million from retail investors [3] - Zhejiang Dongfang saw a net inflow of 25.02 million from institutional investors, while retail investors had a net outflow of 54.71 million [3]

格隆汇1月9日丨九鼎投资(600053.SH)公布，财务部门初步测算，预计2025年度归属于上市公司股东的 净利润为负值，公司2025年度经营业绩将出现亏损。公司将严格遵循《上海证券交易所股票上市规则》 等相关规定，加快推进财务核算工作，尽快披露2025年度业绩预告。最终财务数据请以公司正式披露的 2025年年度报告为准。 ...

证券日报网讯 1月9日，九鼎投资发布公告称，公司预计2025年度归属于上市公司股东的净利润为负 值，2025年度经营业绩将出现亏损。 （文章来源：证券日报） ...

Core Viewpoint - Jiuding Investment (600053) announced on January 9 that it expects a negative net profit attributable to shareholders for the fiscal year 2025, indicating an anticipated operating loss for the year [1]. Group 1 - The company disclosed that its financial department has conducted preliminary calculations regarding its 2025 performance [1]. - On January 9, Jiuding Investment's stock price increased by 6.8%, closing at 22.3 yuan per share, with a total market capitalization of 9.668 billion yuan [1].

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Group 1 - The core viewpoint of the article indicates that Jiuding Investment (600053) is expected to report a negative net profit attributable to shareholders for the fiscal year 2025, suggesting a projected operational loss for the company in that year [1] Group 2 - The company’s financial department has conducted preliminary calculations regarding its performance for 2025, leading to the expectation of a decline in profitability [1]